The purpose of this intensive course is to provide an integrated view of key aspects of basic and clinical cancer research, and novel translational approaches. The course is divided in two parts. The first part is for registered PhD students taking the course for full credits, while the second part is for all members of the research community. PhD students can also take only the second part with 1 credit.
- The first part will depend on the active participation of the people attending the course. Students from the local institutions (UNIL, EPFL) will work in close coordination with experts/tutors to prepare and give presentations on various topics. These will include basic biological mechanisms of cancer development as well as specific tumor types and clinical problems. Outside participants taking the course for credits will be asked to write a review document for one of the above topics, to be provided at the end.
- The second part of the course will be based on the participation of outside outstanding investigators in the cancer research field. Each will be allotted 1.5-2 hours of time, for a retrospective as well as prospective view of their field, with a focus on personal contributions and how they were achieved. Speakers will extend their participation beyond lecturing time, to allow for informal interactions with the course participants.
❖ For the detailed program see below.
❖ REGISTRATION IS NOW CLOSED. However, if you want information, please contact by email Ms Françoise Flejszman (Francoise.Flejszman@unil.ch)
❖ Registration deadline for UNIL / EPFL students : June 1st, 2012.
❖ Registration deadline for outside participants : August 1st, 2012.
❖ Attendance fee (for outside participants only) : $ 600
❖ Outside participants will be responsible for their own travel and lodging arrangements.
❖ Course credits : 4
❖ Swiss Animal Accreditation Days : 4
Program
Part I: Students' teaching
Part II: Outstanding Cancer Researchers Presentations
You may get a printable version of Part II program by clicking on Download PDF.
| Time |
Title |
Speakers |
|---|
Sept. 5th (1 – 3 PM) |
"The sentinel lymph node in tumor immunomodulation" |
Melody Swartz
(EPFL, Lausanne, Switzerland)
|
Sept. 5th (3 – 5 PM) |
“Causes and consequences of microRNA dysregulation in cancer” |
Carlo Croce
(Ohio State University, USA)
|
Sept. 5th (5 – 7 PM) |
"Neurofibromatosis: the genetic disease, tumor models, and beyond" |
Luis Parada
(UT Southwestern, USA)
|
Sept. 6th (9 – 11 AM) |
“Understanding the biology of melanocytes and melanoma cells to develop new strategies for therapy” |
Meenhard Herlyn
(The Wistar Institute, USA)
|
Sept. 6th (11 AM – 1 PM) |
“The Double-Edged Sword of Notch Signaling in Cancer” |
Jon Aster
(Harvard University, USA)
|
Sept. 6th (2 – 4 PM) |
“Tracking and Targeting Breast Cancer Stem Cells” |
Jeff Rosen
(Baylor College of Medicine, USA)
|
Sept. 6th (4 – 6 PM) |
“Interactions between tumor cells and lymphatic vessels in cancer progression: New diagnostic, prognostic and therapeutic tools” |
Michael Detmar
(ETH, Zürich, Switzerland)
|
Sept. 7th (9 – 11 AM) |
"How my Pop-up Toaster Dream came True" |
Erwin Epstein
(Children's Hospital Oakland Research, USA)
|
Sept. 7th (11 AM – 1 PM) |
“TOR signaling in growth and metabolism” |
Michael Hall
(University of Basel, Switzerland)
|
Sept. 7th (2 – 4 PM) |
“EGFR and HER2: Prototypes of Future Cancer Therapy” |
Yossi Yarden
(Weizmann Institute of Science, Israel)
|
Last update: Monday, August 27, 2012
|